Answers are grounded in this paper and cite their sources.
(TXTL) systems. It represents a transformative platform for advancing bacteriophage therapy. Building on experimental work that demonstrates (i) modular genome assembly, (ii) high-yield phage TXTL systems, and (iii) smart hydrogel encapsulation, we explore how synthetic cells can address major limitations in phage therapy. The promising advances include point-of-care phage manufacturing, logic-responsive antimicrobial biomaterials, and new chassis to dissect the dynamics of phage-host interactions. We also propose a roadmap for the deployment of synthetic cells as programmable and evolvable tools in the context of laboratory research and translational clinical adoption.
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: